UPDATE 1-Lilly, Junshi Biosciences plan to start human trials of COVID-19 antibody in Q2
UPDATE 1-Lilly, Junshi Biosciences plan to start human trials of COVID-19 antibody in Q2
(Adds details on the antibody, preclinical study results, background)
(添加有關抗體的詳細信息，臨牀前研究結果，背景)
May 26 (Reuters) - Shanghai Junshi Biosciences Co Ltd 1877.HK said on Tuesday it plans to start clinical studies to test its experimental antibody against COVID-19 in the United States and China in the second quarter of the year, with partner Eli Lilly and Co LLY.N .
路透5月26日電-上海君士生物科學有限公司1877.HK週二表示，計劃於今年第二季度開始臨牀研究，與合作伙伴禮來公司(Eli Lilly And Co LLY.N)合作，在美國和中國測試其針對新冠肺炎的實驗性抗體。
Lilly and several other drugmakers such as Gilead Sciences GILD.O , Pfizer Inc PFE.N and Merck & Co Inc MRK.N are racing to develop treatments or vaccines for the fast-spreading respiratory illness caused by the novel coronavirus.
禮來公司和其他幾家製藥商，如Gilead Sciences GILD.O，輝瑞公司(Pfizer Inc PFE.N)和默克公司(Merck&Co Inc MRK.N)正在競相開發治療或疫苗，以治療由新型冠狀病毒引起的快速傳播的呼吸道疾病。
Junshi said the companies intend to file an application to begin human testing of one of their two antibodies - protective proteins produced in response to infection - tested first in rhesus monkeys.
Junshi説，這兩家公司打算提交申請，開始對他們的兩種抗體中的一種進行人體測試-感染時產生的保護蛋白-首先在恆河猴身上進行測試。
Shanghai Junshi said results from the preclinical studies, published in the science journal Nature, show that both the tested antibodies, called CA1 and CB6, showed substantial neutralization activity against the virus.
上海君士説，發表在科學雜誌“自然”(Nature)上的臨牀前研究結果顯示，這兩種被測試的抗體，即CA1和CB6，都顯示出很強的中和病毒活性。
The company said CB6, which showed a greater reduction in virus levels in the monkeys, will be advanced to human trials.
該公司表示，CB6顯示猴子體內的病毒水平下降幅度更大，將進入人體試驗。
Separately, Merck on Tuesday announced a deal and multiple partnerships to develop vaccines and test an antiviral drug against COVID-19.
另外，默克公司週二宣佈了一項協議和多個合作伙伴關係，以開發疫苗並測試一種針對新冠肺炎的抗病毒藥物。
譯文內容由第三人軟體翻譯。